Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.44 USD | -2.52% | -6.79% | -7.03% |
Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
Financials (USD)
Sales 2024 * | 624M | Sales 2025 * | 171M | Capitalization | 8.63B |
---|---|---|---|---|---|
Net income 2024 * | 4.25B | Net income 2025 * | -999M | EV / Sales 2024 * | 3.73 x |
Net cash position 2024 * | 6.3B | Net cash position 2025 * | 5.1B | EV / Sales 2025 * | 20.7 x |
P/E ratio 2024 * |
2.05
x | P/E ratio 2025 * |
-8.4
x | Employees | 904 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.8% |
Latest transcript on Roivant Sciences Ltd.
1 day | -1.91% | ||
1 week | -6.14% | ||
Current month | -0.26% | ||
1 month | +6.51% | ||
3 months | -2.30% | ||
6 months | +3.16% | ||
Current year | -6.39% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Gline
CEO | Chief Executive Officer | 40 | 16-02-29 |
Richard Pulik
DFI | Director of Finance/CFO | - | 21-09-27 |
Eric Venker
PSD | President | 37 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 53 | 23-03-12 | |
Keith Manchester
BRD | Director/Board Member | 55 | 13-12-31 |
Dan Gold
BRD | Director/Board Member | 56 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.81% | 4 M€ | +20.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-17 | 10.44 | -2.52% | 4 038 049 |
24-04-16 | 10.71 | -1.20% | 4,731,756 |
24-04-15 | 10.84 | -0.91% | 5,009,268 |
24-04-12 | 10.94 | -2.06% | 6,347,143 |
24-04-11 | 11.17 | -0.27% | 3,439,453 |
Delayed Quote Nasdaq, April 17, 2024 at 03:20 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.39% | 8.63B | |
+28.76% | 673B | |
+24.81% | 551B | |
-8.08% | 348B | |
+14.92% | 317B | |
+5.79% | 288B | |
+2.47% | 210B | |
-0.02% | 204B | |
-9.98% | 195B | |
-11.69% | 145B |
- Stock Market
- Equities
- ROIV Stock